Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. In nasopharyngeal carcinoma (NPC), Fas-ligand (Fas-L)-mediated apoptosis might contribute to the immune privilege of tumors. In some cancers, dysregulation of Fas-L protein in tumors might lead to disease progression. The purpose of this study was to evaluate the correlations between Fas-L expression and the clinical outcomes in patients with NPC. Methods. We recruited 78 patients with primary NPC, classified clinical stages according to the 1997 American Joint Committee on Cancer staging system, and assessed Fas-L with immunohistochemical methods. Results. Forty-one (53%) of 78 patients were Fas-L-positive. The prevalence was 0%, 57%, 58%, and 82% from stages I to IV, respectively (p < .001). Fas-L expression was associated with the N classification (p = .05) but not the T classification. Patients with positive Fas-L expression had a lower rate of disease-free survival and overall survival (p = .01 for all log-rank tests). Conclusion. Patients with NPC with Fas-L-positive tumors had higher clinical stages and lymph node metastasis at diagnosis and poorer disease-free survival and overall survival; therefore, Fas-L expression may be a potential biomarker of prognosis.

Original languageEnglish
Pages (from-to)977-983
Number of pages7
JournalHead and Neck
Volume26
Issue number11
DOIs
Publication statusPublished - 2004 Nov 1

Fingerprint

Fas Ligand Protein
Disease-Free Survival
Neoplasms
Survival
Neoplasm Staging
Disease Progression
Biomarkers
Lymph Nodes
Nasopharyngeal carcinoma
Apoptosis
Neoplasm Metastasis
Proteins

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

@article{7d810ce5e891455eb2178adb277b5a62,
title = "Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma",
abstract = "Background. In nasopharyngeal carcinoma (NPC), Fas-ligand (Fas-L)-mediated apoptosis might contribute to the immune privilege of tumors. In some cancers, dysregulation of Fas-L protein in tumors might lead to disease progression. The purpose of this study was to evaluate the correlations between Fas-L expression and the clinical outcomes in patients with NPC. Methods. We recruited 78 patients with primary NPC, classified clinical stages according to the 1997 American Joint Committee on Cancer staging system, and assessed Fas-L with immunohistochemical methods. Results. Forty-one (53{\%}) of 78 patients were Fas-L-positive. The prevalence was 0{\%}, 57{\%}, 58{\%}, and 82{\%} from stages I to IV, respectively (p < .001). Fas-L expression was associated with the N classification (p = .05) but not the T classification. Patients with positive Fas-L expression had a lower rate of disease-free survival and overall survival (p = .01 for all log-rank tests). Conclusion. Patients with NPC with Fas-L-positive tumors had higher clinical stages and lymph node metastasis at diagnosis and poorer disease-free survival and overall survival; therefore, Fas-L expression may be a potential biomarker of prognosis.",
author = "Ho, {Sheng Yow} and How-Ran Guo and Chen, {Helen H.W} and Jenn-Ren Hsiao and Jin, {Yin Tai} and Sen-Tien Tsai",
year = "2004",
month = "11",
day = "1",
doi = "10.1002/hed.20090",
language = "English",
volume = "26",
pages = "977--983",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma. / Ho, Sheng Yow; Guo, How-Ran; Chen, Helen H.W; Hsiao, Jenn-Ren; Jin, Yin Tai; Tsai, Sen-Tien.

In: Head and Neck, Vol. 26, No. 11, 01.11.2004, p. 977-983.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma

AU - Ho, Sheng Yow

AU - Guo, How-Ran

AU - Chen, Helen H.W

AU - Hsiao, Jenn-Ren

AU - Jin, Yin Tai

AU - Tsai, Sen-Tien

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Background. In nasopharyngeal carcinoma (NPC), Fas-ligand (Fas-L)-mediated apoptosis might contribute to the immune privilege of tumors. In some cancers, dysregulation of Fas-L protein in tumors might lead to disease progression. The purpose of this study was to evaluate the correlations between Fas-L expression and the clinical outcomes in patients with NPC. Methods. We recruited 78 patients with primary NPC, classified clinical stages according to the 1997 American Joint Committee on Cancer staging system, and assessed Fas-L with immunohistochemical methods. Results. Forty-one (53%) of 78 patients were Fas-L-positive. The prevalence was 0%, 57%, 58%, and 82% from stages I to IV, respectively (p < .001). Fas-L expression was associated with the N classification (p = .05) but not the T classification. Patients with positive Fas-L expression had a lower rate of disease-free survival and overall survival (p = .01 for all log-rank tests). Conclusion. Patients with NPC with Fas-L-positive tumors had higher clinical stages and lymph node metastasis at diagnosis and poorer disease-free survival and overall survival; therefore, Fas-L expression may be a potential biomarker of prognosis.

AB - Background. In nasopharyngeal carcinoma (NPC), Fas-ligand (Fas-L)-mediated apoptosis might contribute to the immune privilege of tumors. In some cancers, dysregulation of Fas-L protein in tumors might lead to disease progression. The purpose of this study was to evaluate the correlations between Fas-L expression and the clinical outcomes in patients with NPC. Methods. We recruited 78 patients with primary NPC, classified clinical stages according to the 1997 American Joint Committee on Cancer staging system, and assessed Fas-L with immunohistochemical methods. Results. Forty-one (53%) of 78 patients were Fas-L-positive. The prevalence was 0%, 57%, 58%, and 82% from stages I to IV, respectively (p < .001). Fas-L expression was associated with the N classification (p = .05) but not the T classification. Patients with positive Fas-L expression had a lower rate of disease-free survival and overall survival (p = .01 for all log-rank tests). Conclusion. Patients with NPC with Fas-L-positive tumors had higher clinical stages and lymph node metastasis at diagnosis and poorer disease-free survival and overall survival; therefore, Fas-L expression may be a potential biomarker of prognosis.

UR - http://www.scopus.com/inward/record.url?scp=8444223227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8444223227&partnerID=8YFLogxK

U2 - 10.1002/hed.20090

DO - 10.1002/hed.20090

M3 - Article

C2 - 15390195

AN - SCOPUS:8444223227

VL - 26

SP - 977

EP - 983

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 11

ER -